Amgen Inc.

AMGN-Q

NASDAQ:AMGN

258.60
1.50 (0.58%)
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm.
More at Wikipedia

Analysis and Opinions about AMGN-Q

Signal
Opinion
Expert
HOLD
HOLD
October 10, 2017

Hold or Sell? Within biotech and picking a single name, this company would be the way to do it. They are more diversified. They’ve had a few good quarters in a row beating earnings, and are still only trading at 14-16 levels. Putting up pretty good growth. Now that we are more comfortable with interest rates not going to the moon, that takes off the risk, opening up the door to make this more investable.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
October 10, 2017

Hold or Sell? Within biotech and picking a single name, this company would be the way to do it. They are more diversified. They’ve had a few good quarters in a row beating earnings, and are still only trading at 14-16 levels. Putting up pretty good growth. Now that we are more comfortable with interest rates not going to the moon, that takes off the risk, opening up the door to make this more investable.

HOLD
HOLD
September 19, 2017

A fairly inexpensive stock from a valuation standpoint. One of the granddaddies of biotech. This is probably a good hold here. The whole biotech area is getting a bit of a bid under it. There has been more positive action within that whole sector.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
September 19, 2017

A fairly inexpensive stock from a valuation standpoint. One of the granddaddies of biotech. This is probably a good hold here. The whole biotech area is getting a bit of a bid under it. There has been more positive action within that whole sector.

HOLD
HOLD
September 14, 2017

They create drugs similar to other bio-similar drugs. The competitive threats in biologics are a little bit similar. They got approval this morning for a biologic drug. He would like to see them consolidate here.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
September 14, 2017

They create drugs similar to other bio-similar drugs. The competitive threats in biologics are a little bit similar. They got approval this morning for a biologic drug. He would like to see them consolidate here.

COMMENT
COMMENT
August 17, 2017

A fabulous company and has done very well, but their drugs are very mature and make up a very large piece of their total revenue and portfolio. They are spending a lot of money on R&D which has some promise, but no guarantee that they are going to be able to replace the revenue flow. The stock is trading at about 12X earnings. Prefers something that has more current opportunities and a deeper pipeline.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
August 17, 2017

A fabulous company and has done very well, but their drugs are very mature and make up a very large piece of their total revenue and portfolio. They are spending a lot of money on R&D which has some promise, but no guarantee that they are going to be able to replace the revenue flow. The stock is trading at about 12X earnings. Prefers something that has more current opportunities and a deeper pipeline.

COMMENT
COMMENT
July 24, 2017

Trading range would be between $129 and about $180. Generally, he likes breakouts, but the chart shows that breakouts in the past have failed. He would be a little concerned with this.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
July 24, 2017

Trading range would be between $129 and about $180. Generally, he likes breakouts, but the chart shows that breakouts in the past have failed. He would be a little concerned with this.

COMMENT
COMMENT
June 9, 2017

He would advocate Gilead (GILD-Q) instead. It has one of the strongest hepatitis C franchises in the world. This stock is down 58% from its all-time high and trading at less than 9X earnings with a wonderful management team.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
June 9, 2017

He would advocate Gilead (GILD-Q) instead. It has one of the strongest hepatitis C franchises in the world. This stock is down 58% from its all-time high and trading at less than 9X earnings with a wonderful management team.

HOLD
HOLD
May 19, 2017

He likes this as an investment. It could be a core health care holding in any portfolio. They’ve generated tremendous cash flow and have a very strong balance sheet.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
May 19, 2017

He likes this as an investment. It could be a core health care holding in any portfolio. They’ve generated tremendous cash flow and have a very strong balance sheet.

DON'T BUY
DON'T BUY
May 17, 2017

To take out the idiosyncratic risk, he would play Biotechs through the ETF iShares NASDAQ BioTech (IBB-Q). They all have their individual pipelines, but ultimately are going to trade very similarly, except for idiosyncratic risk, which you want to avoid. He wouldn’t advocate buying Biotech or Pharma right now given the pricing pressure of the policy measures, etc.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
May 17, 2017

To take out the idiosyncratic risk, he would play Biotechs through the ETF iShares NASDAQ BioTech (IBB-Q). They all have their individual pipelines, but ultimately are going to trade very similarly, except for idiosyncratic risk, which you want to avoid. He wouldn’t advocate buying Biotech or Pharma right now given the pricing pressure of the policy measures, etc.

HOLD
HOLD
May 10, 2017

A larger cap pure play biotech company, that has a deep pipeline in bio-similars. He doesn’t see competition in the near term for their drug Enbrow (?), which is 3%-2.5% of their top line. They have some drugs that have come off patent, and need to backfill on the top line. One way they were looking to do this was through the PCSK9 drug, a cardio cholesterol lowering drug. Initially they came out with positive results. He bought a Put for some protection. A great balance sheet and an OK yield and modest growth. He is monitoring this. Rates it as a very strong Hold.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
May 10, 2017

A larger cap pure play biotech company, that has a deep pipeline in bio-similars. He doesn’t see competition in the near term for their drug Enbrow (?), which is 3%-2.5% of their top line. They have some drugs that have come off patent, and need to backfill on the top line. One way they were looking to do this was through the PCSK9 drug, a cardio cholesterol lowering drug. Initially they came out with positive results. He bought a Put for some protection. A great balance sheet and an OK yield and modest growth. He is monitoring this. Rates it as a very strong Hold.

COMMENT
COMMENT
April 13, 2017

A great company. It is considered a biotech company, but has a market cap of over $1 billion. Trading at only 13X earnings and has a great free cash flow yield of almost 12%. He feels their pipeline is really strong and that the value of the company is 20% higher than it is here.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
April 13, 2017

A great company. It is considered a biotech company, but has a market cap of over $1 billion. Trading at only 13X earnings and has a great free cash flow yield of almost 12%. He feels their pipeline is really strong and that the value of the company is 20% higher than it is here.

TOP PICK
TOP PICK
March 7, 2017

This is cheap, trading at roughly 13X versus the S&P at 17.4X. It has a free cash flow yield of roughly 8% plus a pretty good dividend yield of 2.56%. It is going to grow its dividend probably in the 10%-15% range. The stock is undervalued and underloved. It has held up really well despite all the tweets and all the other things going on. It is a biotech company, but it is one of the best and certainly one of the biggest. (Analysts’ price target is $189.50.)

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
March 7, 2017

This is cheap, trading at roughly 13X versus the S&P at 17.4X. It has a free cash flow yield of roughly 8% plus a pretty good dividend yield of 2.56%. It is going to grow its dividend probably in the 10%-15% range. The stock is undervalued and underloved. It has held up really well despite all the tweets and all the other things going on. It is a biotech company, but it is one of the best and certainly one of the biggest. (Analysts’ price target is $189.50.)

PAST TOP PICK
PAST TOP PICK
February 22, 2017

(A Top Pick June 22/16. Up 17.47%.) He knew we were coming into some volatile times back in June, and this is one of the dominant biotech companies. Really likes their PCSK9 cholesterol drug, which is going to be a blockbuster.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
February 22, 2017

(A Top Pick June 22/16. Up 17.47%.) He knew we were coming into some volatile times back in June, and this is one of the dominant biotech companies. Really likes their PCSK9 cholesterol drug, which is going to be a blockbuster.

BUY
BUY
January 30, 2017

A health care stock that has been beaten up through the headlines. It is cheap and she likes it. It took a bigger hit than it should have. There is more than 20% upside according to analysts. They have quite a few drugs in phase III trials.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
January 30, 2017

A health care stock that has been beaten up through the headlines. It is cheap and she likes it. It took a bigger hit than it should have. There is more than 20% upside according to analysts. They have quite a few drugs in phase III trials.

BUY
BUY
January 26, 2017

He likes it and likes the space. He likes the bio-based companies. He owns CELG-Q. He cannot say anything too negative about AMGN-Q. It is trading at about 12 times earnings so good value, 7% cash flow yield and they are expanding their portfolio. There is good runway for them.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
January 26, 2017

He likes it and likes the space. He likes the bio-based companies. He owns CELG-Q. He cannot say anything too negative about AMGN-Q. It is trading at about 12 times earnings so good value, 7% cash flow yield and they are expanding their portfolio. There is good runway for them.

DON'T BUY
DON'T BUY
January 25, 2017

If you look at their operating economics, they are very much like a large Pharmaceutical company. Relatively slow moving. Their rate of innovation and patent expiration on all products kind of match, so there is not a lot of upside. The growth that has occurred, much of it on a trailing basis, has come from rising prices on their rheumatoid arthritis drug, but will no longer be able to do that. His belief is that prices are coming down.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
January 25, 2017

If you look at their operating economics, they are very much like a large Pharmaceutical company. Relatively slow moving. Their rate of innovation and patent expiration on all products kind of match, so there is not a lot of upside. The growth that has occurred, much of it on a trailing basis, has come from rising prices on their rheumatoid arthritis drug, but will no longer be able to do that. His belief is that prices are coming down.

Showing 16 to 30 of 105 entries